Possible synergies between isatin, an endogenous MAO inhibitor, and antiparkinsonian agents on the dopamine release from striatum of freely moving rats.
- 1 July 2020
- journal article
- research article
- Published by Elsevier in Neuropharmacology
- Vol. 171, 108083
Abstract
No abstract availableKeywords
Funding Information
- University of Vigo (0022 122F641.02)
This publication has 54 references indexed in Scilit:
- The real catecholamine content of secretory vesicles in the CNS revealed by electrochemical cytometryScientific Reports, 2013
- Isatin‐binding proteins of rat and mouse brain: Proteomic identification and optical biosensor validationProteomics, 2009
- Interplay between Cytosolic Dopamine, Calcium, and α-Synuclein Causes Selective Death of Substantia Nigra NeuronsNeuron, 2009
- Determination of isatin and monoamine neurotransmitters in rat brain with liquid chromatography using palladium hexacyanoferrate modified electrodeAnalytica Chimica Acta, 2006
- Tribulin and Endogenous MAO-Inhibitory Regulation In VivoNeuroToxicology, 2004
- Comparative Study of the Effects of Isatin, an Endogenous MAO-Inhibitor, and Selegiline on Bradykinesia and Dopamine Levels in a Rat Model of Parkinson’s Disease Induced by the Japanese Encephalitis VirusNeuroToxicology, 2004
- The Endogenous Oxindoles 5-Hydroxyoxindole and Isatin Are Antiproliferative and ProapoptoticBiochemical and Biophysical Research Communications, 2000
- Isatin, an Endogenous MAO Inhibitor, as a New Biological ModulatorCNS Drug Reviews, 1999
- Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents — preclinical studiesNeuroscience & Biobehavioral Reviews, 1997
- Effects ofl-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated ratsBrain Research, 1990